丹麦制药巨头 Novo 将采用 Anthropic 的 Claude 推进 AI 药物研发

英文标题：🔶 Danish pharma giant Novo to use Anthropic's Claude to advance AI drug discovery

丹麦制药公司 Novo（原名 Novo Nordisk、Ozempic 的开发商）宣布与 Anthropic 合作，计划利用 Claude 及 Claude Science 加速新药研发。双方称，AI 将提升研发生产力，并帮助研究人员理解人体生物学和药物作用机制。Novo 此前已与 OpenAI 合作采用 GPT-Rosalind，同时还参与了丹麦 AI 超级计算机 Gefion 的建设。该合作反映出大型药企正将前沿大模型进一步部署到药物发现、临床开发和相关科研流程中。

打开原文相关 2 · 机会 0

中文

发布于 2026/09/16 - 17:26 GMT+2

丹麦制药公司 Novo（原名 Novo Nordisk、Ozempic 的开发商）已与 Anthropic 建立合作伙伴关系，旨在利用人工智能加速新药开发。

“与 Anthropic 联手将极大增强我们的研发组织能力，并帮助我们推进为慢性病患者带来全新、变革性健康解决方案的使命，”Novo 总裁兼首席执行官 Mike Doustdar 周三在一份新闻稿中表示。

该公司宣布，这家制药巨头将使用 Anthropic 的模型和 Claude Science，提升研发（R&D）中的科学推理能力。

Novo 的 CEO 表示，除了提高研发生产力外，AI 工具还能带来“全新的科学机遇”，并有助于对人体生物学和药物作用机制进行推理与理解。

Anthropic 联合创始人兼 CEO Dario Amodei 表示：“AI 能力的不断提升，带来了将原本需要一个世纪才能实现的生物学和医学突破压缩至十年内完成的潜力。”

他补充称，若让顶尖研究人员能够使用安全、强大且值得信赖的前沿模型，就有可能缩短研究周期、改善研究成果，并发现能够显著改善人类生活的药物和治疗方法。

此次合作正值 Novo 加码押注 AI 以加快药物研究之际。这家制药巨头在今年 4 月达成合作后，已经开始使用 OpenAI 的科学研究模型 GPT-Rosalind，以分析复杂数据集、识别潜在药物，并缩短从研究到患者获得治疗之间的时间。

2024 年，Novo Nordisk Foundation 与 Nvidia 以及丹麦出口与投资基金（EIFO）合作成立丹麦 AI 创新中心，该中心运营 Gefion——丹麦首台面向 AI 的超级计算机。

Anthropic 也在扩大其生命科学领域的业务。2026 年 5 月，这家科技公司宣布与百时美施贵宝（Bristol Myers Squibb）合作，在该公司的研究、临床开发、制造、商业及企业职能部门部署 Claude。

English / 原文

Published on 16/09/2026 - 17:26 GMT+2

Novo, previously Novo Nordisk, the Danish pharmaceutical company behind Ozempic, has partnered with Anthropic to accelerate the development of new medicines using artificial intelligence.

“Joining forces with Anthropic will supercharge our R&D organisation and help us on our mission to bring new, transformative health solutions to people living with chronic diseases,“ said Mike Doustdar, president and CEO of Novo, in a press release Wednesday.

The pharmaceutical giant will use Anthropic’s models and Claude Science to advance scientific reasoning for Research and Development (R&D), the company announced.

Beyond increasing productivity in R&D, Novo’s CEO said AI tools can offer “completely new scientific opportunities” and help reasoning and understanding of human biology and drug mechanics.

"AI’s increasing capability brings with it the potential to compress a century’s worth of biological and medical breakthroughs into a decade," said Dario Amodei, co-founder and CEO of Anthropic.

He added that by giving leading researchers access to safe, capable, and trusted frontier models, it is possible to shorten research timelines, improve outcomes, and discover medicines and treatments that significantly improve human life.

This partnership comes amid Novo’s bet on AI to fast-track drug research. The pharma giant is already using OpenAI’s science GPT-Rosalind, after sealing the deal in April to use advanced AI to analyse complex datasets, identify potential drugs, and cut the time between research and patient access.

In 2024, the Novo Nordisk Foundation partnered with Nvidia and the Export and Investment Fund of Denmark (EIFO) to establish the Danish Centre for AI Innovation, which operates Gefion – Denmark's first AI-ready supercomputer.

Anthropic is also expanding its work in the life sciences sector. In May 2026, the tech company announced a collaboration with Bristol Myers Squibb to deploy Claude across the company's research, clinical development, manufacturing, commercial, and corporate functions.